EGFR and non-small cell lung carcinoma: In the phase II Ascent study (14), which recruited patients with stage III EGFR-mutated NSCLC, the MPR rate was 57.1% (4/7), and the pCR rate was 14.3% (1/7) in 7 patients who underwent surgery.